Lynn M. Bjerke

2.6k citations

13 papers · 2.0k · 1 hit paper · h-index 10

Impact in

Genetics top 1%
- Glioma Diagnosis and Treatment
Molecular Biology top 10%
- PI3K/AKT/mTOR signaling in cancer
- Epigenetics and DNA Methylation
- Genomics and Chromatin Dynamics
- Chromatin Remodeling and Cancer

Papers in

Genetics 7
- Glioma Diagnosis and Treatment 7
Molecular Biology 5
- PI3K/AKT/mTOR signaling in cancer 3
- Receptor Mechanisms and Signaling 1
- Renal and related cancers 1

Co-authors: Paul Workman (3 shared papers)Paul Andrew Clarke (2 shared papers)Timothy Anthony Yap (1 shared paper)Chris Jones (4 shared papers)Alan G. Mackay (3 shared papers)Diana M. Carvalho (3 shared papers)Rui Manuel Reis (2 shared papers)Sergey Popov (2 shared papers)
Journals: Neuro-Oncology (3 papers)Cancer Cell (2 papers)Nature Medicine (1 paper)PLoS Genetics (1 paper)Cancer Discovery (1 paper)
Partner nations: United Kingdom United States Brazil

In The Last Decade

Lynn M. Bjerke

12 papers receiving 2.0k citations

Lynn M. Bjerke's Hit Papers

align trajectories log scale

Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma 2017 · 851 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2017 Cancer Cell

Peers

Countries citing papers authored by Lynn M. Bjerke

Since Specialization

Citations

This map shows the geographic impact of Lynn M. Bjerke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynn M. Bjerke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynn M. Bjerke more than expected).

Fields of papers citing papers by Lynn M. Bjerke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lynn M. Bjerke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynn M. Bjerke. The network helps show where Lynn M. Bjerke may publish in the future.

Co-authors

The 25 scholars most cited alongside Lynn M. Bjerke, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lynn M. Bjerke Line = papers co-authored together Lynn M. Bjerke links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work
1	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma Cancer Cell ·Alan G. Mackay, Anna Burford, Diana M. Carvalho, Elisa Izquierdo, Janat Fazal Salom, Kathryn R. Taylor, Lynn M. Bjerke, Matthew Clarke Hit paper breakdown →	2017	851
2	Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases Cancer Research ·Florence I. Raynaud, Suzanne A. Eccles, Paul Andrew Clarke, Angela Hayes, Bernard P. Nutley, Sonia Alix, Alan T. Henley, Francesca Di-Stefano	2007	312
3	Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN Cancer Discovery ·Lynn M. Bjerke, Alan G. Mackay, Meera Nandhabalan, Anna Burford, Alexa Jury, Sergey Popov, Dorine A. Bax, Diana M. Carvalho	2013	259
4	Recurrent MET fusion genes represent a drug target in pediatric glioblastoma Nature Medicine ·Sebastian Bender, Susanne N. Gröbner, Elke Pfaff, Marcel Kool, Paul A. Northcott, Dominik Sturm, Barbara Christine Worst, Stefan M. Pfister	2016	191
5	Drugging PI3K in cancer: refining targets and therapeutic strategies Current Opinion in Pharmacology ·Timothy Anthony Yap, Lynn M. Bjerke, Paul Andrew Clarke, Paul Workman	2015	186
6	Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma Cell Cycle ·Sandrine Guillard, Paul Andrew Clarke, Robert te Poele, Zahra Mohri, Lynn M. Bjerke, Melanie R. Valenti, Florence I. Raynaud, Suzanne A. Eccles	2009	63
7	GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant Cancer Cell ·Ilon Liu, Gustavo Alencastro Veiga Cruzeiro, Lynn M. Bjerke, Rebecca F. Rogers, Yura Grabovska, Alexander Beck, Alan G. Mackay, Tara Barron	2024	37
8	Chemical Genetics Reveals an RGS/G-Protein Role in the Action of a Compound PLoS Genetics ·Kevin J. Fitzgerald, Svetlana Tertyshnikova, Lynn M. Bjerke, Ben Burley, Jian Jing Cao, Pamela M. Carroll, Robert K. M. Choy, Steve Doberstein	2006	29
9	Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition Proceedings of the National Academy of Sciences ·Aleksandra B. Bielen, Gary Box, Lara Perryman, Lynn M. Bjerke, Sergey Popov, Yann Jamin, Alexa Jury, Melanie R. Valenti	2012	28
10	The prognostic role of intragenic copy number breakpoints and identification of novel fusion genes in paediatric high grade glioma Acta Neuropathologica Communications ·Diana M. Carvalho, Alan G. Mackay, Lynn M. Bjerke, Richard Guy Grundy, María Celeste Lopes, Rui Manuel Reis, Chris Jones	2014	21
11	PDTM-33. ATRX LOSS CONFERS ENHANCED SENSITIVITY TO COMBINED PARP INHIBITION AND RADIOTHERAPY IN PAEDIATRIC GLIOBLASTOMA MODELS Neuro-Oncology ·Janat Fazal Salom, Lynn M. Bjerke, Diana M. Carvalho, Jessica K.R. Boult, Alan G. Mackay, Helen N. Pemberton, Valeria Molinari, Matthew Clarke	2018	5
12	MODL-20. A BIOBANK OF ~100 PATIENT-DERIVED MODELS REPRESENTING BIOLOGICAL HETEROGENEITY AND DISTINCT THERAPEUTIC DEPENDENCIES IN PAEDIATRIC HIGH GRADE GLIOMA AND DIPG Neuro-Oncology ·Diana M. Carvalho, Alan G. Mackay, Sara Temelso, Elisa Izquierdo, Elisabet Fernandez, Rebecca F. Rogers, Jessica K.R. Boult, Janat Fazal Salom	2020	2
13	HGG-23. DRUG SCREENING LINKED TO MOLECULAR PROFILING IDENTIFIES NOVEL DEPENDENCIES IN PATIENT-DERIVED PRIMARY CULTURES OF PAEDIATRIC HIGH GRADE GLIOMA AND DIPG Neuro-Oncology ·Alan G. Mackay, Valeria Molinari, Diana M. Carvalho, Helen N. Pemberton, Sara Temelso, Anna Burford, Matthew Clarke, Mariama Fofana	2018	0

About Lynn M. Bjerke

Lynn M. Bjerke is a scholar working on Genetics, Molecular Biology, Nuclear Energy and Engineering, Waste Management and Disposal and Infectious Diseases, having authored 13 papers that have together received 2.0k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (7 papers), PI3K/AKT/mTOR signaling in cancer (3 papers), Receptor Mechanisms and Signaling (1 paper) and Renal and related cancers (1 paper). The work is most often cited by research in Genetics (878 citations), Molecular Biology (444 citations), Cancer Research (66 citations), Aging (4 citations) and Oncology (46 citations). Lynn M. Bjerke has collaborated with scholars based in United Kingdom, United States and Brazil. Frequent co-authors include Paul Workman, Paul Andrew Clarke, Timothy Anthony Yap, Chris Jones, Alan G. Mackay, Diana M. Carvalho, Rui Manuel Reis, Sergey Popov, Alexa Jury and Darren R. Hargrave. Their work appears in journals such as Neuro-Oncology, Cancer Cell, Nature Medicine, PLoS Genetics and Cancer Discovery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Lynn M. Bjerke

Impact in

Papers in i

In The Last Decade

Lynn M. Bjerke

Lynn M. Bjerke's Hit Papers

Peers

Countries citing papers authored by Lynn M. Bjerke

Fields of papers citing papers by Lynn M. Bjerke

All Works

About Lynn M. Bjerke

Explore authors with similar magnitude of impact

Papers in